Triptans and CGRP blockade – impact on the cranial vasculature

The Journal of Headache and Pain

Review Article

Francesca Marchese¹  Messoud Ashina²  Anne Luise Vollesen³  Francesca Cortese⁴  Christian Lampl⁵  Alejandro Labastida-Ramírez⁶  Silvia Benemei⁷  Lanfranco Pellesi⁸  Michele Romoli⁹ 

[1] Child Neuropsichiatry Unit, University of Palermo, Palermo, Italy;Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medicl Sciences, University of Copenhagen, Copenhagen, Denmark;Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Latina, Italy;Department of Neurogeriatric Medicine, Headache Medical Center Linz, Linz, Austria;Dept Internal Medicine, Division of Vascular Pharmacology, Erasmus Medical Center, Rotterdam, The Netherlands;Health Sciences Department, University of Florence, and Headache Centre, Careggi University Hospital, Viale Pieraccini 6, 50134, Florence, Italy;Medical Toxicology Headache and Drug Abuse Center, University of Modena and Reggio Emilia, Modena, Italy;Neurology Clinic, University Hospital of Perugia, Perugia, Italy;

关键词: Triptans;    Calcitonin gene related peptide – CGRP;    Anti-CGRP (receptor) monoclonal antibodies – mAbs;    Middle meningeal artery;    Middle cerebral arteries;    Migraine models;    Magnetic resonance angiography (MRA);   

DOI  :  10.1186/s10194-017-0811-5

 received in 2017-08-02, accepted in 2017-09-25,  发布年份 2017

来源: Springer

【 摘 要 】

The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and migraine pharmacological triggers may act in perivascular space. This review reports the effects of triptans and CGRP blocking molecules on cranial vasculature in humans, focusing on their specific relevance to migraine treatment.

【 授权许可】

CC BY   
© The Author(s). 2017